ANDAORALFOR SUSPENSION
Approved
Dec 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Mechanism of Action
drugs. [see Microbiology ]
Indications (13)
the following infections in adultsskin structure infections Urinary tract infections Limitations of Useindicating no beta-lactamase productionAmoxicillinclavulanate potassium should not be useddevelopment of drug-resistant bacteriamaintain the effectiveness of Amoxicillinclavulanate potassiumother antibacterial drugsclavulanate potassium should be used only to treatprevent infectionsstrongly suspected to be caused by susceptible bacteriastrongly suspected to be caused by bacteria